Amgen (AMGN) Cash from Investing Activities Growth (3y) (2012 - 2026)
Powered by 
Analysis
Amgen (AMGN) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -39.19% |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -177.73% |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 46.78% |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 66.14% |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -44.69% |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | -246.81% |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -72.08% |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | - |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn | 27.84% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -39.19% |
| Mar 31, 2026 | -36.21% |
| Dec 31, 2025 | 41.56% |
| Sep 30, 2025 | -15.74% |
| Jun 30, 2025 | 43.81% |
| Mar 31, 2025 | -59.10% |
| Dec 31, 2024 | -20.46% |
| Sep 30, 2024 | -69.58% |
| Jun 30, 2024 | -29.65% |
| Mar 31, 2024 | 12.05% |
| Dec 31, 2023 | -169.50% |
| Sep 30, 2023 | 45.61% |
| Jun 30, 2023 | 53.94% |
| Mar 31, 2023 | 99.20% |
| Dec 31, 2022 | 16.49% |
| Sep 30, 2022 | -27.03% |
| Jun 30, 2022 | -40.93% |
| Mar 31, 2022 | -26.64% |
| Dec 31, 2021 | 63.26% |
| Sep 30, 2021 | -59.90% |